About Us

Decheng Capital is an investment firm that provides capital and strategic support to early-stage life science companies with revolutionary technologies and growth stage healthcare companies with strong market presence. We are a group of dedicated professionals with complementary expertise to build highly successful companies globally. Founded in 2012, Decheng continues to capitalize on a historic opportunity in the rapid growth of healthcare industry as well as breakthroughs in life science research. With over $2 billion in capital and the support from some of the most prestigious limited partners in the world, Decheng is poised to create value for our investors and entrepreneur partners.


Founded in 2012

Asset Under Management

Over $2 billion of capital

Your Partner

Preferred partners for entrepeneurs, world-class scientists and strategic partners

Recent News

November 15, 2022

CG Oncology Raises $120 Million in Oversubscribed Series E Financing                           ;

September 28, 2022

Professor Dennis Lo, Decheng's Advisor, Wins 2022 Lasker Award

September 22, 2022

Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing


November 10, 2020

Exclusive: Decheng's Inside View of Merck's $2.75 Billion Acquisition of VelosBio                                               

October 12, 2020

Exclusive: How Sequencing Firm ReadCoor Came to be Acquired by 10x Genomics                                   

September 23, 2020

Exclusive: The Story Behind How Cirina, a $12 Million Hong Kong Diagnostics Startup, Became Part of Illumina